Veradermics Quarterly Balance Sheet
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veradermics financial position
As of Jun 30, 2026, Veradermics reported total assets of $825.7 million against total liabilities of $12.1 million. Shareholders' equity stood at $813.6 million, or 98.5% of assets. The company held $319.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 70.53, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 319.33M | 168.41M | 21.77M | 8.60M | 32.44M | 53.08M |
| Short-Term Investments | 500.56M | 222.38M | 120.10M | — | — | 0 |
| Total Current Assets | 824.75M | 397.07M | 152.49M | — | — | 55.53M |
| Property, Plant & Equipment | 41.00K | 21.00K | 22.00K | — | — | 0 |
| Total Assets | 825.74M | 397.36M | 152.62M | — | — | 55.53M |
| Accounts Payable | 5.92M | 1.07M | 2.13M | — | — | 2.25M |
| Total Current Liabilities | 11.69M | 6.72M | 9.15M | — | — | 4.72M |
| Total Liabilities | 12.12M | 6.72M | 9.16M | — | — | 4.72M |
| Shareholders' Equity | 813.61M | 390.64M | -121.01M | -76.07M | -60.67M | -48.48M |
| Retained Earnings | -174.16M | -150.65M | -123.42M | — | — | -49.23M |
| Net Cash (Debt) | 819.89M | 390.80M | 141.86M | 8.60M | 32.44M | 53.08M |
| Shares Outstanding | 41.78M | 37.34M | 749.76K | — | — | 736.93K |
This table shows 6 quarterly periods of Veradermics's balance sheet, from Q2 2026 back to Q4 2024, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a balance sheet?